divarasib
AXP000025.1 · Targeted small molecule
- Platform
- small molecule
- Targets
- KRAS
- Originator
- Genentech
- Sponsor
- Genentech (Roche)
Names
Cross-references
- NCI Thesaurus
- C173995
- Wikidata
- Q123118541
- FDA UNII
- E6S21PVT91
Approvals
No regulatory approval recorded.
Clinical trials (15)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) | Recruiting | Phase 3 | 2026-10-06 | 2032-01-31 | 400 | Non-small Cell Lung Cancer |
| NCT06793215 | A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Recruiting | Phase 3 | 2025-10-24 | 2028-11-30 | 600 | KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer |
| NCT06835465 | A Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Participants | Completed | Phase 1 | 2025-02-21 | 2025-05-06 | 18 | Healthy Participants |
| NCT06734208 | A Study to Evaluate the Pharmacokinetics of Divarasib in Healthy Participants and Participants With Impaired Hepatic Function | Completed | Phase 1 | 2025-01-31 | 2025-11-27 | 31 | Hepatic Impairment |
| NCT06690138 | A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants | Completed | Phase 1 | 2024-11-15 | 2025-02-11 | 18 | Healthy Participants |
| NCT06677957 | A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants | Completed | Phase 1 | 2024-11-06 | 2024-12-30 | 19 | Healthy Participants |
| NCT06497556 | A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer | Active not recruiting | Phase 3 | 2024-09-23 | 2026-05-19 | 338 | KRAS G12C Lung Cancer; Non-Small Cell Lung Cancer |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Recruiting | Phase 1/2 | 2023-06-20 | 2032-01-29 | 320 | Non-Small Cell Lung Cancer |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study | Recruiting | Phase 3 | 2023-06-01 | 2033-03-01 | 200 | Cancer |
| NCT04929223 | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Recruiting | Phase 1 | 2021-10-22 | 2030-08-31 | 542 | Metastatic Colorectal Cancer |
| NCT04589845 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Active not recruiting | Phase 2 | 2021-01-18 | 2032-09-25 | 920 | Solid Tumors |
| NCT04302025 | A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Active not recruiting | Phase 2 | 2020-11-06 | 2026-11-30 | 99 | Non-small Cell Lung Cancer |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Active not recruiting | Phase 1 | 2020-07-29 | 2027-12-31 | 498 | Advanced Solid Tumors; Colorectal Cancer; Non-Small Cell Lung Cancer |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | Active not recruiting | Phase 2/3 | 2017-09-22 | 2027-06-30 | 1000 | Non-Small Cell Lung Cancer |
| NCT07783009 | An Expanded Access Program to Provide Divarasib to Participants With Previously Treated KRAS G12c-Positive Advanced or Metastatic Non-Small Cell Lung Cancer | Available | Non-Small Cell Lung Cancer |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42929675 | Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC. | The New England journal of medicine | 2026 | cited by trial NCT06497556 |
| PMID 40086048 | Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. | European journal of cancer (Oxford, England : 1990) | 2025 | cited by trial NCT04589845 |
| PMID 40525978 | Update on Liquid Biopsy. | Radiology | 2025 | cited by trial NCT03178552 |
| PMID 40632992 | Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | cited by trial NCT04449874 |
| PMID 41213248 | Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features. | Journal of the National Comprehensive Cancer Network : JNCCN | 2025 | cited by trial NCT04589845 |
| PMID 38052910 | Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. | Nature medicine | 2024 | cited by trial NCT04449874 |
| PMID 38190582 | Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan. | JCO precision oncology | 2024 | cited by trial NCT03178552 |
| PMID 38898120 | Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial. | Nature medicine | 2024 | cited by trial NCT03178552 |
| PMID 38995268 | Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 | name in title: divarasib |
| PMID 37611121 | Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. | The New England journal of medicine | 2023 | cited by trial NCT04449874 |
| PMID 35995953 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. | Nature medicine | 2022 | cited by trial NCT03178552 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41506251 | In-Source Fragmentation of Pyrrolidine-Containing KRAS Scaffolds Leads to Enhanced Structure Elucidation and Tandem Mass Spectral Quality. | Journal of the American Society for Mass Spectrometry | 2026 | name in abstract: GDC-6036 |
| PMID 41766690 | Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C. | Journal of medicinal chemistry | 2026 | name in title: divarasib |
| PMID 41769711 | Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C. | Journal of medicinal chemistry | 2026 | name in abstract: divarasib |
| PMID 41784211 | A Systematic Review of the Efficacy of KRAS p.G12C Inhibitors in Metastatic Colorectal Cancer: The Current State of Science. | Cancer investigation | 2026 | name in abstract: divarasib |
| PMID 42098425 | Evaluating the efficacy of G12C inhibitors in conjunction with Gamma Knife radiosurgery for KRAS-mutant non-small cell lung cancer brain metastases. | Journal of neuro-oncology | 2026 | name in abstract: divarasib |
| PMID 42365001 | Covalent pan-TEAD inhibitors block YAP activity and demonstrate brain penetrance in a Hippo-dependent cancer model. | Nature communications | 2026 | name in abstract: divarasib |
| PMID 42485897 | Development and validation of an LC-MS/MS method for the quantification of the KRASG12C inhibitor divarasib. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences | 2026 | name in title: divarasib |
| PMID 42511798 | KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. | International journal of molecular sciences | 2026 | name in abstract: divarasib |
| PMID 42551924 | [Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions]. | Gan to kagaku ryoho. Cancer & chemotherapy | 2026 | name in abstract: divarasib |
| PMID 42622884 | KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms. | Medical oncology (Northwood, London, England) | 2026 | name in abstract: divarasib |
| PMID 42633623 | A Highly Atroposelective Negishi Coupling Enables the Commercial Manufacturing Process of Divarasib. | Chimia | 2026 | name in title: divarasib |
| PMID 42759542 | Targeting KRAS-Mutant Lung Cancers. | Journal of the National Comprehensive Cancer Network : JNCCN | 2026 | name in abstract: divarasib |
| PMID 42841489 | Variant-selective and pan-RAS inhibitors enhance targeted agent activity in patient-derived multi-cell type tumor spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: divarasib |
| PMID 42945155 | Divarasib Bests 1st-Generation KRASG12C Inhibitors. | Cancer discovery | 2026 | name in title: divarasib |
| PMID 42975930 | Rapid target engagement of KRAS G12C tricomplex inhibitor RO3903 overcomes resistance and drives durable tumor regression. | Proceedings of the National Academy of Sciences of the United States of America | 2026 | name in abstract: divarasib |
| PMID 42984346 | Variant-Selective and Pan-RAS Inhibitors Enhance Targeted Agent Activity in Patient-Derived Multi-cell-type Tumor Spheroids. | Molecular cancer therapeutics | 2026 | name in abstract: divarasib |
| PMID 43003982 | Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC. | Nature reviews. Clinical oncology | 2026 | name in title: divarasib |
| PMID 39914665 | Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors. | Annals of oncology : official journal of the European Society for Medical Oncology | 2025 | name in abstract: divarasib |
| PMID 40023579 | In vitro metabolism of targeted covalent inhibitors and their thiol conjugates by gut microbiome from rats, mice, and humans. | Drug metabolism and disposition: the biological fate of chemicals | 2025 | name in abstract: divarasib |
| PMID 40116975 | Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials. | Medical oncology (Northwood, London, England) | 2025 | name in abstract: divarasib |
| PMID 40274247 | KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials. | Critical reviews in oncology/hematology | 2025 | name in abstract: divarasib |
| PMID 40297021 | Potency and Safety of KRAS G12C Inhibitors in Solid Tumors: A Systematic Review. | Clinical Medicine Insights. Oncology | 2025 | name in abstract: divarasib |
| PMID 40447141 | Recent advances in therapeutic targeting of the KRAS pathway in cancer. | Pharmacology & therapeutics | 2025 | name in abstract: divarasib |
| PMID 40597785 | The complex journey of targeting RAS in oncology. | BMC cancer | 2025 | name in abstract: GDC-6036 |
| PMID 40608319 | RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy. | Cancer research | 2025 | name in abstract: divarasib |
| PMID 40640254 | Binding modes of the KRAS(G12C) inhibitors GDC-6036 and LY3537982 revealed by all atom molecular dynamics simulations. | Scientific reports | 2025 | name in title: GDC-6036 |
| PMID 41408054 | Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy. | Nature communications | 2025 | name in abstract: divarasib |
| PMID 38542278 | Targeting KRAS G12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. | International journal of molecular sciences | 2024 | name in abstract: divarasib |
| PMID 38739329 | Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC. | Targeted oncology | 2024 | name in title: divarasib |
| PMID 39051157 | High Resolution Ion Mobility Enables the Structural Characterization of Atropisomers of GDC-6036, a KRAS G12C Covalent Inhibitor. | Journal of the American Society for Mass Spectrometry | 2024 | name in title: GDC-6036 |
| PMID 39360933 | An updated overview of K-RAS G12C inhibitors in advanced stage non-small cell lung cancer. | Future oncology (London, England) | 2024 | name in abstract: divarasib |
| PMID 40391409 | The structure of KRASG12C bound to divarasib highlights features of potent switch-II pocket engagement. | Small GTPases | 2024 | name in title: divarasib |
| PMID 36876898 | Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry. | Analytical chemistry | 2023 | name in abstract: GDC-6036 |
| PMID 37162129 | Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036. | Organic letters | 2023 | name in title: GDC-6036 |
| PMID 37673947 | Early promising results with the novel KRASG12C inhibitor divarasib. | Nature reviews. Clinical oncology | 2023 | name in title: divarasib |
| PMID 37774359 | Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors. | Journal of medicinal chemistry | 2023 | name in abstract: divarasib |
| PMID 36083155 | Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. | Analytical chemistry | 2022 | name in abstract: GDC-6036 |
| PMID 36326518 | Atroposelective Negishi Coupling Optimization Guided by Multivariate Linear Regression Analysis: Asymmetric Synthesis of KRAS G12C Covalent Inhibitor GDC-6036. | Journal of the American Chemical Society | 2022 | name in title: GDC-6036 |
| PMID 36358848 | KRAS in NSCLC: State of the Art and Future Perspectives. | Cancers | 2022 | name in abstract: GDC-6036 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R21CA297690 | Noncovalent interaction of mutant KRAS inhibitors | DUKE UNIVERSITY | CHI, JEN-TSAN ASHLEY | 2025–2025 | name in abstract: divarasib |
Notes
KRAS G12C covalent. Roche code RG6330. UNII is free base; adipate salt is separate NCIt C203123 / UNII OA9191WV3C.
How to cite
divarasib (AXP000025.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000025.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.